摘要
1例74岁女性左侧输尿管癌(高级别尿路上皮癌)患者接受替雷利珠单抗静脉滴注200 mg(1次/3周)。患者于2021年10月24日至2022年2月21日行5次免疫治疗前,实验室检查空腹血糖均在正常范围内,非住院期间未监测血糖。于2022年5月入院行免疫治疗前实验室检查示:葡萄糖36.93 mmol/L,糖化血红蛋白7.9%,空腹C肽0.27 ng/ml,血β羟丁酸0.24 mmol/L,诊断为暴发性1型糖尿病,给予降糖、补液、纠正水电解质及酸碱平衡治疗26 d后,患者血糖控制稳定。
A 74-year-old female patient with left-sided carcinoma of ureter(high-grade urothelial carcinoma)received tislelizumab 200 mg intravenously once every 3 weeks.The patient's fasting blood glucose was in the normal range before 5 times of immunotherapy from October 24,2021 to February 21,2022.Blood glucose was not monitored during the non-hospitalization period.Before admission to the hospital in May 2022,the actual laboratory examination showed that glucose was 36.93 mmol/L,glycosylated hemoglobin was 7.9%,fasting C-peptide was 0.27 ng/ml,and blood β-hydroxybutyric acid was 0.24 mmol/L.The patient was diagnosed with fulminant type 1 diabetes mellitus.After 26 days of treatment of hypoglycemia,rehydration,correction of water electrolysis and acid-base balance,the patient's blood glucose was stable.
作者
张靖
王飞
彭净
张春雨
Zhang Jing;Wang Fei;Peng Jing;Zhang Chunyu(Department of Pharmacy,Dongming People's Hospital,Dongming 274500,China;Department of Respiratory and Critical Care Medicine,Dongming People's Hospital,Dongming 274500,China;Department of Pharmacy,Affiliated Hospital of Jining Medical University,Jining 272000,China)
出处
《实用药物与临床》
CAS
2024年第2期126-129,共4页
Practical Pharmacy and Clinical Remedies
